Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03969537 · ClinicalTrials.gov registry record
Telemedicine Follow-up for Patients With Cervical Dystonia Treated With Neurotoxin Injections
A clinical trial, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- 27
- Enrollment target
NCT03969537: Completed study, sponsored by Vanderbilt University Medical Center.
NCT03969537 is a clinical trial that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03969537 has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- 27 participants
- Enrollment target
Study Summary
Many cervical dystonia (CD) patients are limited in their ability to travel to the clinic for follow-up in between injection visits. A telemedicine visit at the time of peak effectiveness of neurotoxin treatment may be valuable in informing the neurologist's choice of muscle selection and/or dose for the next injection visit. The primary objective of this study is to investigate both patient and physician satisfaction with the use of our telemedicine tool for this type of follow-up. After assessment of the subject, the neurologist will decide whether or not the telemedicine visit was informative to the upcoming injection visit. Subjects will answer questions at the end of the visit regarding their satisfaction with the follow-up and overall telemedicine communication. The principle investigator will complete a similar survey with additional questions about information gathered from the visit to assess the primary objective. A secure video communications platform will be used for the visit, which will occur 2-4 weeks after the patient's last neurotoxin injection (around the time of peak effectiveness). The investigating neurologist will remotely assess the patient and make notes for the next injection visit.
Primary Outcome
This questionnaire measures patient satisfaction with the telehealth visit scored 7 to 27
Interventions
- OTHER Telemedicine follow-up visit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2020-06-04 |
What the finished NCT03969537 record still lists
NCT03969537 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 27 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Telemedicine follow-up visit is the first listed.
NCT03969537 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03969537 about?
NCT03969537 is a clinical study titled "Telemedicine Follow-up for Patients With Cervical Dystonia Treated With Neurotoxin Injections". Many cervical dystonia (CD) patients are limited in their ability to travel to the clinic for follow-up in between injection visits. A telemedicine visit at the time of peak effectiveness of neurotoxin treatment may be valuable in informing the neurologist's choice of muscle selection and/or dose f...
What is the current status of trial NCT03969537?
This trial is currently completed. The enrollment target is 27 participants. The study started on 2019-04-01. Estimated completion is 2020-06-04.
What interventions are being tested in trial NCT03969537?
The interventions under investigation include: Telemedicine follow-up visit (OTHER).
Who is sponsoring clinical trial NCT03969537?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI